Key result
Lipoprotein X spuriously elevates LDL-C by up to ~40% in cholestasis, mimicking hypercholesterolemia.
Why the study?
In patients with cholestasis-associated dyslipidemia, the accumulation of lipoprotein X strongly interferes with routine clinical assays, causing spurious abnormalities that can mislead diagnostic and therapeutic decisions.
In patients with cholestasis-associated dyslipidemia, lipoprotein X causes spurious elevations in total and LDL cholesterol as well as pseudohyponatremia, requiring apoB-specific testing to avoid overestimating ASCVD risk and targeted treatment of the underlying biliary obstruction rather than indiscriminate statin therapy.
Answers are grounded in this paper and cite their sources.
May support avoiding routine statins in cholestasis; leaves open prospective validation of LpX assays.
INTRODUCTION: Cholestasis is a pathologic condition characterized by impaired bile excretion and the reflux of bile components into the systemic circulation, leading to their subsequent accumulation. Dyslipidemia is 1 of its most characteristic complications, driven primarily by the formation and accumulation of lipoprotein X (LpX). Its aberrant accumulation not only contributes to the pathologic injury cascade of cholestasis but also strongly interferes with routine clinical assays, resulting in spurious abnormalities across multiple parameters and thereby misleading clinical diagnostic and therapeutic decisions. This review summarizes the proposed formation hypotheses, physicochemical properties, and recent advances in detection techniques for LpX. METHODS: We provide an in-depth analysis of the mechanisms underlying its interference with laboratory testing and outline key points for early recognition, optimized detection protocols, and individualized diagnostic and management strategies for LpX in patients with cholestasis-associated dyslipidemia. RESULTS: We emphasize that the core management principle for this patient population lies in the early identification of LpX and targeted intervention for the underlying cholestatic disorder rather than indiscriminate lipid-lowering therapy. DISCUSSION: This review aimed to enhance overall awareness of LpX and provide scientific reference and theoretical support for mechanistic research on cholestasis-related dyslipidemia, standardized lipid management, and precise clinical practice in patients with cholestasis.
No takes yet. Share an insight, caveat, or question.
YUEMAIER et al. (2026) conducted a review in Cholestasis and dyslipidemia. Lipoprotein X (LpX) accumulation vs. Normal lipoprotein profile / LDL was evaluated. Lipoprotein X causes spurious LDL-C elevations up to 40% and pseudohyponatremia in cholestasis, requiring targeted treatment of the biliary disorder rather than routine statin therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: